Lenoss Medical

Lenoss Medical, Inc. is a Providence, Rhode Island-based biomedical company developing biological solutions for the physiological repair of skeletal defects, with an initial focus on osteoporotic fractures of the spinal column. Its flagship product is the OsteoPearl Vertebral Body Augmentation (VBA) system, an implant and surgical instrument platform intended to allow physicians to place natural bone tissue into damaged vertebrae. The company positions OsteoPearl as a fully biological alternative to conventional vertebral augmentation, which relies on injecting bone cement, plastic or epoxy into the fractured vertebral body; Lenoss states its approach stabilizes the fracture while relying on the natural healing properties of healthy bone tissue.

The clinical problem the company addresses is vertebral compression fracture in osteoporotic patients. Company materials cite roughly 1.5 million vertebral compression fractures per year in the United States, an estimated 8.9 million osteoporotic fractures worldwide annually, and a 19.2% chance of an additional fracture within 12 months of an initial vertebral fracture, along with consequences including back pain, immobility, deformity and increased morbidity and mortality when fractures go untreated. Management has also cited risks associated with epoxy-based kyphoplasty, such as embolism, and has noted that allograft bone material does not carry organ-transplant-style rejection risk because it contains no living cells.

By March 2026 the company described itself as a growth-stage business with a commercial organization spanning sales, marketing and operations, product development engineers, a board of directors and a group of clinical/medical advisors including orthopedic surgery and interventional radiology specialists.

Founding story

Lenoss Medical was founded by Dom Messerli, who serves as Founder, President, CEO and Chairman of the Board. Messerli trained as a mechanical engineer at the University of Bern in Switzerland and joined Synthes, where he held product development and marketing leadership roles during the growth of Synthes Spine, later serving as Director of R&D leading acquisition, integration and transformation work for Johnson & Johnson's DePuy Synthes Spine organization after Synthes was acquired by J&J. He has said the idea for the company grew out of his division's expertise in allograft bone tissue implants for spinal surgery combined with the recognition that osteoporotic spinal compression fractures were being treated with injected plastic or epoxy rather than with solutions that permit bone healing. He also holds an Executive MBA from Penn State University and is named as an inventor on medical device patents used across spine specialties.

Business model

Lenoss Medical develops and commercializes an implant and surgical instrument system (OsteoPearl) for vertebral body augmentation, sold into the spinal vertebral augmentation market. The company solicits distributor inquiries for the OsteoPearl VBA system and employs a direct commercial team including a VP of Sales, area sales managers, and an executive director of sales strategy and operations.

Revenue derives from commercial sales of the OsteoPearl implant and instrument system used in vertebral augmentation procedures; the company also pursues distribution partnerships for the product.

Traction

The company reported record sales in the fourth quarter preceding its March 2026 financing announcement, with year-over-year surgical procedure growth of nearly 150%. Earlier funding was intended to finance a human clinical study and move toward product commercialization, and ACTIVATE program funds supported the addition of clinical study sites.

Latest developments

On March 17, 2026, Lenoss Medical announced the close of a $6 million growth bridge financing, adding new investor Arizona Venture Capital alongside existing investors Xcellerant Ventures, Right Hill Ventures, Highpoint Ventures, Beacon Angels, the Magpie Neurosurgical Innovation Venture Fund and a healthcare-focused family office. The proceeds are directed toward commercial expansion, additional regional sales leadership, clinical data generation, and scaling operational and marketing capabilities.